FOR PATIENTS · SOURCE READING

Treatment of Aggressive Non-Hodgkin Lymphoma

Source: Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: August 22, 2024 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Mantle-cell-specific source passages within broader non-Hodgkin lymphoma sections Only selected blocks explicitly name mantle cell lymphoma. Full owning sections include other lymphomas and must not be relabeled mantle-cell-only.

Context from the original source

Other treatments depend on the type of aggressive non-Hodgkin lymphoma. Treatment may include the following:

For mantle cell lymphoma, monoclonal antibody therapy with combination chemotherapy, followed by stem cell transplant. Monoclonal antibody therapy may be given afterwards as maintenance therapy (treatment that is given after initial therapy to help keep cancer from coming back).

Source links and citations

Preserved source evidence · Independent clinical review pending · Not medical advice